Thus, our results presented here possibly have broader implications beyond DYT-PRKRA. Luteolin may also be useful for treating diseases triggered by inflammation where involvement of PACT-PKR pathway has been established such as in hepatic stellate cells, which are major contributors for the progression of hepatic fibrosis (Nakamura et al., 2015). This evidence concerns the gene EIF2AK2 and Hepatic fibrosis.